These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 20347978

  • 1. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
    Gathercole LL, Stewart PM.
    J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
    [Abstract] [Full Text] [Related]

  • 2. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW.
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [Abstract] [Full Text] [Related]

  • 3. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP.
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M.
    Handb Exp Pharmacol; 2011 Jan; (203):127-46. PubMed ID: 21484570
    [Abstract] [Full Text] [Related]

  • 5. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR.
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [Abstract] [Full Text] [Related]

  • 6. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM, Seckl JR.
    Front Horm Res; 2008 Feb; 36():146-164. PubMed ID: 18230901
    [Abstract] [Full Text] [Related]

  • 7. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH, Walker BR.
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [Abstract] [Full Text] [Related]

  • 8. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD, Azevedo I, Monteiro R, Martins MJ.
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Dhote V, Sharma A, Jain M.
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [Abstract] [Full Text] [Related]

  • 10. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
    Draper N, Stewart PM.
    J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
    [Abstract] [Full Text] [Related]

  • 11. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
    Stewart PM.
    Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
    [Abstract] [Full Text] [Related]

  • 12. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
    Lagos CF, Vecchiola A, Allende F, Fuentes CA, Tichauer JE, Valdivia C, Solari S, Campino C, Tapia-Castillo A, Baudrand R, Villarroel P, Cifuentes M, Owen GI, Carvajal CA, Fardella CE.
    Mol Cell Endocrinol; 2014 Mar 25; 384(1-2):71-82. PubMed ID: 24447464
    [Abstract] [Full Text] [Related]

  • 13. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS, Rhee SD, Jung WH, Kang NS, Kim HY, Kang SK, Ahn JH, Kim KY.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):19-27. PubMed ID: 22760069
    [Abstract] [Full Text] [Related]

  • 14. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R, Huang Y, Liang G, Li X.
    Curr Med Chem; 2010 Sep 15; 17(5):412-22. PubMed ID: 20015040
    [Abstract] [Full Text] [Related]

  • 15. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
    Diederich S, Quinkler M, Mai K, Schöneshöfer M, Baehr V, Pfeiffer A, Oelkers W, Eigendorff E.
    Horm Metab Res; 2011 Jan 15; 43(1):66-71. PubMed ID: 20925019
    [Abstract] [Full Text] [Related]

  • 16. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
    Jun YJ, Park SJ, Kim TH, Lee SH, Lee KJ, Hwang SM, Lee SH.
    J Allergy Clin Immunol; 2014 Oct 15; 134(4):926-934.e6. PubMed ID: 24810847
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M, Seckl JR.
    Drug Discov Today; 2007 Jul 15; 12(13-14):504-20. PubMed ID: 17631244
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
    Blum A, Favia AD, Maser E.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):132-6. PubMed ID: 18822345
    [Abstract] [Full Text] [Related]

  • 20. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
    Abdallah BM, Beck-Nielsen H, Gaster M.
    Eur J Clin Invest; 2005 Oct 25; 35(10):627-34. PubMed ID: 16178882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.